Lipella Pharmaceuticals Inc.
LIPO
$2.36
-$0.345-12.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.31% | 43.79% | -22.77% | 27.84% | 23.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.31% | 43.79% | -22.77% | 27.84% | 23.64% |
| Cost of Revenue | 17.91% | 133.88% | 25.61% | -37.44% | 21.46% |
| Gross Profit | -24.03% | -166.56% | -32.52% | 44.78% | -21.02% |
| SG&A Expenses | -10.98% | 42.00% | -21.42% | -31.58% | 2.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.87% | 91.09% | 5.41% | -35.28% | 13.39% |
| Operating Income | -9.05% | -98.92% | -7.57% | 39.55% | -12.28% |
| Income Before Tax | -9.62% | -109.28% | -9.14% | 39.03% | -11.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.62% | -109.28% | -9.14% | 39.03% | -11.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.62% | -109.28% | -9.14% | 39.03% | -11.61% |
| EBIT | -9.05% | -98.92% | -7.57% | 39.55% | -12.28% |
| EBITDA | -9.06% | -99.01% | -7.54% | -- | -- |
| EPS Basic | 51.42% | -46.38% | 29.85% | 53.95% | 12.08% |
| Normalized Basic EPS | 51.42% | -46.39% | 29.86% | 53.96% | 12.08% |
| EPS Diluted | 51.15% | -45.57% | 29.85% | 54.31% | 13.82% |
| Normalized Diluted EPS | 51.42% | -46.39% | 29.86% | 53.96% | 12.08% |
| Average Basic Shares Outstanding | 125.65% | 42.98% | 55.60% | 32.41% | 26.95% |
| Average Diluted Shares Outstanding | 125.65% | 42.98% | 55.60% | 32.41% | 26.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |